Mark Curtis
Mark is a Business Development Analyst at the Centre for Commercialization of Regenerative Medicine (CCRM), where he collaborates with the team to help evaluate the commercial potential of regenerative medicine and cell therapy technologies. He began his career at Princess Margaret Hospital studying cellular reprogramming of human skin cells. Following this project, he left the laboratory and took on a role with Bloom Burton & Co., a healthcare-focused investment dealer. While there he supported the advisory team in carrying out scientific diligence on early-stage biotechnology companies. Prior to joining CCRM he was a consultant to Stem Cell Therapeutics, a Toronto-based biotechnology company focused on developing therapeutics targeting cancer stem cells. Mark received a Master’s degree from the University of New South Wales in Sydney, where he studied the directed differentiation of embryonic stem cells, and a Bachelor’s degree in Biology, from Queen’s University. Follow Mark on Twitter @markallencurtis
Posts by: Mark
Regenerative Medicine Deal Review: August
. Welcome to your deal review for the month of August. As would be expected at the end of the summer news flow was modest, but Northwest Biotherapeutics kept things alive with a $17.5 million financing via convertible debt, while Gamida Cell announced a game-changing deal with a large Pharma partner that is placing its […]
Update from the Clinic: July
. Welcome to your Update from the Clinic for the month of July. The cancer stem cell companies were back in the news last month. OncoMed initiated its ALPINE clinical trial of Tarextumab for pancreatic cancer, while Stemline Therapeutics announced an investigational new drug (IND) for SL-401 and initiation of clinical trials in two blood […]
Regenerative Medicine Deal Review: July
. Welcome to your deal review for the month of July. There was financing activity this past month as StemCells and Fate Therapeutics each secured $20 million in funding. Bluebird bio was busy with the acquisition of a privately-held genome editing company; clearly a strategic move to strengthen its gene therapy pipeline. Sernova was in […]
Highlights from The Business of Regenerative Medicine Course
. The Centre for Commercialization of Regenerative Medicine (CCRM) just finished hosting the 7th annual Business of Regenerative Medicine course here in Toronto, which saw many notable figures in the space come to weigh-in on a number of critical issues relevant to commercialization in the world of regenerative medicine and cell therapy (RM). The […]
Update from the Clinic: August
. Welcome to your Update from the Clinic for the month of August. Asterias Biotherapeutics breathes new life into a cell therapy shelved two years ago and initiates a Phase I/II study in patients with spinal cord injury. Northwest Biotherapeutics provides an update on the use of its dendritic cell-based immunotherapy in patients with brain […]